

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2022 November 15; 14(11): 2088-2301



### MINIREVIEWS

- 2088** Portal vein embolization failure: Current strategies and future perspectives to improve liver hypertrophy before major oncological liver resection  
*Cassese G, Han HS, Lee B, Cho JY, Lee HW, Guiu B, Panaro F, Troisi RI*

### ORIGINAL ARTICLE

#### Basic Study

- 2097** Proteomic signatures of infiltrative gastric cancer by proteomic and bioinformatic analysis  
*Zhang LH, Zhuo HQ, Hou JJ, Zhou Y, Cheng J, Cai JC*
- 2108** Potential role of long noncoding RNA RP5-881L22.5 as a novel biomarker and therapeutic target of colorectal cancer  
*Zong H, Zou JQ, Huang JP, Huang ST*
- 2122** Synaptophysin-like 2 expression correlates with lymph node metastasis and poor prognosis in colorectal cancer patients  
*Zhao ZX, Liu QL, Yuan Y, Wang FS*
- 2138** Comprehensive analysis of the potential role and prognostic value of sine oculis homeobox homolog family in colorectal cancer  
*Fang ZX, Li CL, Wu Z, Hou YY, Wu HT, Liu J*
- 2157** KLF16 promotes pancreatic adenocarcinoma cell proliferation and migration by positively regulating SMAD6  
*Mi W, Zheng Z, Lu JD, Duan SQ, Zhang J, Zhang HQ, Ding YX, Yin J, Cao F, Zhang J, Li F*
- 2170** MiR-30e-3p inhibits gastric cancer development by negatively regulating THO complex 2 and PI3K/AKT/mTOR signaling  
*Gu XJ, Li YJ, Wang F, Ye T*
- 2183** E3 ubiquitin ligase TRIM55 promotes metastasis of gastric cancer cells by mediating epithelial-mesenchymal transition  
*Li WW, Yuan H, Kong S, Tian SB*

#### Clinical and Translational Research

- 2195** Missed colorectal cancers in a fecal immunochemical test-based screening program: Molecular profiling of interval carcinomas  
*van der Vlugt M, Carvalho B, Fliers J, Montazeri N, Rausch C, Grobbee EJ, Engeland MV, Spaander MCW, Meijer GA, Dekker E*

**Case Control Study**

- 2208** Oxidative imbalance increases the risk for colonic polyp and colorectal cancer development  
*Tsounis D, Villiotou V, Melpidou A, Pantiou C, Argyrou A, Giannopoulou C, Grigoratou A, Rontogianni D, Mantzaris GJ, Papatheodoridis G*

**Retrospective Study**

- 2224** Predictive value of indirect bilirubin before neoadjuvant chemoradiotherapy in evaluating prognosis of local advanced rectal cancer patients  
*Li SF, Wei R, Yu GH, Jiang Z*

**Observational Study**

- 2238** Features of gastric cancer by anatomic subsite in northern China: A multi-center Health Science Report database study  
*Qu RZ, Ma YP, Bao XY, Tao LY, Zhou X, Lu SY, Zhang Y, Wang BY, Li F, Tuo L, Zhang ZP, Fu W*

**CASE REPORT**

- 2253** A rare synchrony of adenocarcinoma of the ampulla with an ileal gastrointestinal stromal tumor: A case report  
*Matli VVK, Zibari GB, Wellman G, Ramadas P, Pandit S, Morris J*
- 2266** Silent advanced large cell neuroendocrine carcinoma with synchronous adenocarcinoma of the colon: A case report  
*Baek HS, Kim SW, Lee ST, Park HS, Seo SY*
- 2273** Surgical management of monomorphic epitheliotropic intestinal T-cell lymphoma followed by chemotherapy and stem-cell transplant: A case report and review of the literature  
*Bissessur AS, Zhou JC, Xu L, Li ZQ, Ju SW, Jia YL, Wang LB*
- 2288** Surgical treatment of liver inflammatory pseudotumor-like follicular dendritic cell sarcoma: A case report  
*Fu LY, Jiang JL, Liu M, Li JJ, Liu KP, Zhu HT*
- 2295** Rare squamous cell carcinoma of the jejunum causing perforated peritonitis: A case report  
*Xiao L, Sun L, Zhang JX, Pan YS*

**ABOUT COVER**

Associate Editor of *World Journal of Gastroenterology Oncology*, Keun-Yeong Jeong, PhD, Research Assistant Professor, Chief Executive Officer, PearlsinMires, Seoul 03690, South Korea. [alvirus@naver.com](mailto:alvirus@naver.com)

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

**INDEXING/ABSTRACTING**

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJGO as 3.404; IF without journal self cites: 3.357; 5-year IF: 3.250; Journal Citation Indicator: 0.53; Ranking: 162 among 245 journals in oncology; Quartile category: Q3; Ranking: 59 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Gastroenterology is 72/149; Oncology is 203/360.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Xiang-Di Zhang; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

November 15, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Surgical treatment of liver inflammatory pseudotumor-like follicular dendritic cell sarcoma: A case report

Li-Yue Fu, Jiu-Liang Jiang, Meng Liu, Jun-Jun Li, Kai-Ping Liu, Hai-Tao Zhu

**Specialty type:** Oncology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Lin J, China; Sahin TT, Turkey

**Received:** August 16, 2022

**Peer-review started:** August 16, 2022

**First decision:** September 23, 2022

**Revised:** September 28, 2022

**Accepted:** October 17, 2022

**Article in press:** October 17, 2022

**Published online:** November 15, 2022



**Li-Yue Fu, Jiu-Liang Jiang, Meng Liu, Kai-Ping Liu,** Clinical School, Guizhou Medical University, Guiyang 550001, Guizhou Province, China

**Jun-Jun Li, Hai-Tao Zhu,** Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang 550001, Guizhou Province, China

**Corresponding author:** Hai-Tao Zhu, PhD, Doctor, Professor, Surgeon, Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, No. 28 Guiyi Road, Yunnan District, Guiyang 550001, Guizhou Province, China. [205429734@qq.com](mailto:205429734@qq.com)

### Abstract

#### BACKGROUND

Inflammatory pseudotumor-like follicular dendritic cell sarcoma (IPT-like FDCS) is rare with a low malignant potential. Hepatic IPT-like FDCS has similar clinical features to hepatocellular carcinoma (HCC), making it extremely difficult to distinguish between them in clinical practice. We describe the case of a young female patient diagnosed with HCC before surgery, which was pathologically diagnosed as IPT-like FDCS after the left half of the liver was resected. During 6 mo of follow-up, the patient recovered well with no signs of recurrence or metastasis.

#### CASE SUMMARY

A 23-year-old female patient with a 2-year history of hepatitis B presented to the Affiliated Hospital of Guizhou Medical University. She was asymptomatic at presentation, and the findings from routine laboratory examinations were normal except for slightly elevated alpha-fetoprotein levels. However, ultrasonography revealed a 3-cm diameter mass in the left hepatic lobe, and abdominal contrast-enhanced computed tomography revealed that the tumor had asymmetrical enhancement during the arterial phase, which declined during the portal venous phase, and had a pseudo-capsule appearance. Based on the findings from clinical assessments and imaging, the patient was diagnosed with HCC, for which she was hospitalized and had undergone laparoscopic left hepatectomy. However, the tumor specimens submitted for pathological analyses revealed IPT-like FDCS. After surgical removal of the tumor, the patient recovered. In addition, the patient continued to recover well during 6 mo of follow-up.

#### CONCLUSION

Hepatic IPT-like FDCS is difficult to distinguish from HCC. Hepatectomy may provide beneficial outcomes in non-metastatic hepatic IPT-like FDCS.

**Key Words:** Hepatocellular carcinoma; Liver; Pseudotumor-like follicular dendritic cell sarcoma; Surgery; Tumor; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Inflammatory pseudotumor-like follicular dendritic cell sarcoma (IPT-like FDSC) is a type of FDSC with low malignant potential. We investigated the clinical and pathological characteristics, diagnosis, and treatment in a 23-year-old woman diagnosed with hepatic IPT-like FDSC. She underwent laparoscopic left hepatectomy, with an uneventful postoperative course. It is difficult to distinguish hepatic IPT-like FDSC from hepatocellular carcinoma based on clinical features. Therefore, most patients with hepatic IPT-like FDSC are found after surgery. However, surgery may be the best treatment option for patients with hepatic IPT-like FDSC. At present, no abnormality has been found in the patient during the 6-mo follow-up.

**Citation:** Fu LY, Jiang JL, Liu M, Li JJ, Liu KP, Zhu HT. Surgical treatment of liver inflammatory pseudotumor-like follicular dendritic cell sarcoma: A case report. *World J Gastrointest Oncol* 2022; 14(11): 2288-2294

**URL:** <https://www.wjgnet.com/1948-5204/full/v14/i11/2288.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v14.i11.2288>

## INTRODUCTION

Follicular dendritic cell sarcoma (FDSC) is a rare tumor with nonspecific clinical features. FDSC cannot be diagnosed based on clinical findings alone; therefore, its diagnosis depends on pathological examinations of surgically resected tumor specimens. Pathologically, most FDSCs express at least two FDC markers, including CD21, CD35, and CNA-42. There are two morphologic variants of this tumor: Conventional and inflammatory pseudotumor (IPT)-like[1]. The etiology and pathogenesis of IPT-like FDSC are not clear. Its occurrence may coincide with Epstein-Barr virus (EBV) infection, because in cases with confirmed IPT-like FDSC, the positive rate of Epstein-Barr encoding region (EBER) through *in situ* hybridization was as high as 92.1%[2]. EBV-encoded small RNA exists in all tumor cells, and hybridization imprinting tests confirmed that the virus exists in the form of a monoclonal free body, suggesting that EBV infection occurred before FDC tumor proliferation. CD21, the receptor molecule expressed on the surface of FDC, is the receptor of EBV; therefore, scholars speculate that EBV plays an important role in tumor formation. IPT-like FDSC cells are irregularly arranged and IPT-like FDSC presents with lymphocytic infiltrate, with a positive *in situ* hybridization test for (EBV)-encoded RNA [3]. Most IPT-like FDSCs affect the liver and spleen. Herein, we report a rare case of a female patient with liver IPT-like FDSC in the context of hepatitis B virus infection. We investigated the clinical and pathological characteristics, diagnosis, and treatment of IPT-like FDSC.

## CASE PRESENTATION

### Chief complaints

A 23-year-old female patient with an underlying hepatitis B virus infection presented, with no symptoms, at the Affiliated Hospital of Guizhou Medical University.

### History of present illness

She was asymptomatic.

### History of past illness

She had received entecavir as treatment for her hepatitis B infection 2 years previously.

### Personal and family history

The patient had an unremarkable personal and family history.

### Physical examination

There were no significant findings on initial physical examination.



### Laboratory examinations

Laboratory analyses provided the following findings: Hemoglobin, 134 g/L; white blood cell count,  $5.23 \times 10^9$  cells/L; platelet count,  $149 \times 10^9$  cells/L; red blood cell count,  $4.50 \times 10^9$  cells/L; anti-HB test results, positive; serum levels of albumin, 50.40 g/L; aspartate aminotransferase level, 39.50 U/L; alanine aminotransferase level, 23.80 U/L; alkaline phosphatase level, 80 U/L; total bilirubin level, 15.40  $\mu\text{mol/L}$ ; direct bilirubin level, 5.20  $\mu\text{mol/L}$ ; total bilirubin level, 10.20  $\mu\text{mol/L}$ ; hepatitis B viral DNA,  $2.35 \times 10^1$  IU/mL (normal  $\leq 10$  IU/mL); and alpha-fetoprotein (AFP) level, 12.31 ng/mL (normal = 0.00–7.00 ng/mL).

### Imaging examinations

Ultrasonography revealed a 3-cm diameter mass in the left hepatic lobe (Figure 1), necessitating the performance of abdominal contrast-enhanced computed tomography (CT). CT showed asymmetrical tumor enhancement during the arterial phase; however, the enhancement declined during the portal venous phase, and the tumor had a pseudo-capsule appearance (Figure 2).

## FINAL DIAGNOSIS

We initially diagnosed the disease as hepatocellular carcinoma (HCC) based on the findings from clinical, laboratory, and imaging assessments.

## TREATMENT

After discussion with the radiologist, early hepatocellular carcinoma was highly suspected according to the imaging signs and clinical manifestations. There was no other adjuvant treatment for the patient according to the preoperative comprehensive evaluation. Therefore, the patient underwent laparoscopic left hepatectomy.

## OUTCOME AND FOLLOW-UP

Postoperative pathological analysis showed a large number of medium to small lymphocytes distributed in the liver space-occupying lesion area, and an unequal number of spindle or epithelial cells, and histiocyte-like cells, were distributed alternately. Further, hepatic lobule structure was found in the surrounding liver tissue, some small lymphocytes had infiltrated the portal area, and a few small cells were found in the hepatic sinuses.

Immunohistochemical staining showed that the tumor specimen was positive for CD2, CD3, CD5, CD7, CD8, and TIA-1 in all lymphocytes. A portion of the tissue specimen was CD4 positive. Furthermore, positive expressions of CD21, CD35, Ki-67 (30%), and SMA were observed in a portion of the specimen with spindle-epithelioid tumor cells. *In situ* hybridization test was only positive for EBV-encoded RNA in spindle-epithelioid tumor cells (Figure 3). Based on these pathological findings, the patient was diagnosed with IPT-like FDCS. During the 6-mo postoperative follow-up period, the patient had no signs of recurrence or metastasis (Figure 4).

## DISCUSSION


Although IPT-like FDCS is a special type of FDCS, it exhibits characteristic features comparable to those of conventional FDCS[4]. More than 60 cases of IPT-like FDCS have been reported in English literature, mainly located in the liver (more than 20 cases)[5–8] and spleen (more than 30 cases)[9–12], and to a lesser extent in the colon (6 cases)[13–15], lungs (1 case)[16], and pancreas (1 case)[17]. The tumor mainly occurs in middle-aged and elderly people, with a female-to-male ratio of 2.2:1, and a median age of 56.5 years[18].

To date, all reported patients with IPT-like FDCS in the liver presented with fever, jaundice, abdominal pain, and/or anemia as the initial clinical manifestations. In addition, other case reports highlighted paraneoplastic arthritis as an initial clinical manifestation[19,20]. However, the patient in the present case did not experience any clinical manifestations prior to the hospital visit, which shows the peculiarity of the disease in clinical practice. In our case, contrast-enhanced CT showed an asymmetrical tumor enhancement and decline during the arterial and portal venous phases, respectively, with a pseudo-capsule appearance of the tumor; these findings corroborated with those of previous studies[21].



DOI: 10.4251/wjgo.v14.i11.2288 Copyright ©The Author(s) 2022.

**Figure 1 Ultrasonography before surgery.** A: A hypoechoic nodule, about 26 mm × 22 mm in size; B: The nodule with a regular shape, clear boundary, and homogeneous internal echo; C: It can be seen in S4 of the liver.




DOI: 10.4251/wjgo.v14.i11.2288 Copyright ©The Author(s) 2022.

**Figure 2 Abdominal contrast-enhanced computed tomography before surgery.** Nodular abnormal enhancement foci (about 27 mm × 26 mm) can be seen in the left inner lobe of the liver, showing uneven and obvious enhancement in the arterial phase and weakening in the venous phase, and a pseudo-capsule can be seen surrounding it. A-F: Axial position; G-I: Coronal position; J-L: Sagittal position.


Because the imaging manifestations of IPT-like FDCS of the liver are nonspecific, CT usually shows low-density nodule enhancement, which is characterized by non-uniform enhancement in the arterial phase and resolution in the delayed phase. Some highly differentiated HCCs can also show resolution in the delayed phase; therefore, hepatic inflammatory pseudotumor (HIPT)-like FDCS should also be differentiated from HCC with internal necrosis *via* imaging findings. HCC with internal necrosis often has peripheral structural invasion, accompanied by cirrhosis and portal hypertension, and may have tumor thrombus formation. HCC is the most common malignant tumor of the liver. The patient had chronic viral hepatitis, AFP elevation, and imaging findings suggestive of HCC. These signs are consistent with the general clinical manifestations of HCC. Therefore, we should pay attention to the possibility of this disease in addition to the huge mixed echo mass in the liver. If IPT-like FDCS is suspected, it is important to perform routine puncture biopsy. Puncture biopsy is a feasible preoperative diagnostic method for IPT-like FDCS, but many false negative cases have been encountered due to the smaller amount of obtained puncture tissue. Its definitive diagnosis mainly relies on immunohistochemical and *in situ* hybridization analyses of surgically obtained tumor specimens.





DOI: 10.4251/wjgo.v14.i11.2288 Copyright ©The Author(s) 2022.

**Figure 3 Immunohistochemical staining and *in situ* hybridization test.** A: Tissue specimens; B and C: Immunohistochemical results: Proliferative histiocytes CD21 (+), CD35 (+), D2-40 (-), and SMA (+), focal. Lymphocyte hepatocyte (+), CD3 (diffuse), CD20 (-), CD79  $\alpha$  (-), CD10 (-), bcl-2 (-), CD5 (+), CD19 (+), Sox11 (-), CD56 (-), CD4 (+), partial, CD8 (+), minority, cyclin D1 (-), TIA (+), Granzyme B (-), CD2 (+), CD7 (+), bcl-6 (-), MUM1 (-), CD30 (scattered transformed large cells), and TCR-R (-). Ki-67 (about 25%+); D: *In situ* hybridization results: Some cells showed EBER+, positive control +. EBER: Epstein-Barr encoding region.



DOI: 10.4251/wjgo.v14.i11.2288 Copyright ©The Author(s) 2022.

**Figure 4 Abdominal computed tomography after 6 mo of follow-up.** A: After 6 mo of follow-up, the abdominal computed tomography re-examination; B: The re-examination showed that no nodular or strip-shaped high-density shadow in the liver; C: There was no abnormality in the left lobe of the liver.

Apart from HCC, pathological analyses should be performed to distinguish HIPT-like FDCS from other diseases such as HIPT and primary liver lymphoma because the symptoms and imaging findings of HIPT are nonspecific. The histopathological characteristics of HIPT include the presence of inflammatory lesions consisting of diffused and dense hyalinized collagenosis with inflammatory cells, compact foamy histiocyte proliferation, as well as lymphocyte and plasma cell infiltration[22]. In primary liver lymphoma, clinical features are nonspecific as well, and histological analyses demonstrate infiltrations limited to the liver. Among the types of lymphoma, diffuse large B-cell lymphoma is the most common type noted[23,24]. HIPT-like FDCS shows a contrasting lymphocyte infiltration pattern compared with that of FDCS, immunohistochemical analyses show positive expression of one of the FDCS markers (CD21, CD35, CD23, or CNA42) in tumor cells, and *in situ* hybridization testing is positive for EBV-encoded RNA in spindle-epithelioid tumor cells. Clinicians can better diagnose HIPT-like FDCS *via* pathological examinations of surgically resected tissue specimens.

In summary, HIPT-like FDCS displays combined characteristics of chronic inflammation and malignant tumors on imaging. The final diagnosis is dependent on pathology, which shows that the tumor cells express CD21, CD23, CD35, SMA, and other markers, or do not express these antigens, but are EBER positive. HCC, HIPT, and primary liver lymphoma should be considered in the differential diagnosis.

In the treatment of HIPT-like FDCS, complete resection of tumor is the best treatment, but there is still dispute about whether conventional radiotherapy and chemotherapy are needed after surgery. Chemotherapy and/or radiotherapy can be used for patients with recurrence or surgery that cannot be cured[25-27]. The review found that the incidence of HIPT-like FDCS is very low, as are the recurrence and metastasis rate and mortality rate of previously reported liver cases; 4 cases recurred or metastasized, the recurrence rate was 11.8%, and the mortality rate was 2.9%. The remaining cases survived well[2]. In the present case, HIPT-like FDCS was found to be an indolent malignant tumor with no sign of relapse or metastasis noted during the follow-up.

## CONCLUSION

HIPT-like FDCS is extremely difficult to distinguish from HCC due to their similar clinical features. In addition, surgical resection may provide better long-term outcomes in patients with indolent malignant HIPT-like FDCSs.

## ACKNOWLEDGEMENTS

The authors thank Clinical Medical School, Guizhou Medical University, and the Hepatobiliary Department, Affiliated Hospital of Guizhou Medical University.

## FOOTNOTES

**Author contributions:** Fu LY contributed to manuscript writing and editing and data collection; Jiang JL, Liu M, Li JJ, and Liu KP contributed to data analysis; Zhu HT contributed to conceptualization and supervision; all authors have read and approved the final manuscript.

**Supported by** Guizhou Medical University and Affiliated Hospital of Guizhou Medical University.

**Informed consent statement:** Written informed consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Li-Yue Fu 0000-0002-3479-6372; Jiu-Liang Jiang 0000-0002-3479-6356; Hai-Tao Zhu 0000-0002-5388-9021.

**S-Editor:** Fan JR

**L-Editor:** A

**P-Editor:** Fan JR

## REFERENCES

- 1 Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Faveria RD, Delsol G, De Wolf-Peters C, Falini B, Gascoyne RD, Gaulard P, Gatter KC, Isaacson PG, Jaffe ES, Kluin P, Knowles DM, Mason DY, Mori S, Müller-Hermelink HK, Piris MA, Ralfkiaer E, Stein H, Su IJ, Warnke RA, Weiss LM. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. *Histopathology* 2002; **41**: 1-29 [PMID: 12121233 DOI: 10.1046/j.1365-2559.2002.01418.x]
- 2 Ge R, Liu C, Yin X, Chen J, Zhou X, Huang C, Yu W, Shen X. Clinicopathologic characteristics of inflammatory pseudotumor-like follicular dendritic cell sarcoma. *Int J Clin Exp Pathol* 2014; **7**: 2421-2429 [PMID: 24966952]
- 3 Cheuk W, Chan JK, Shek TW, Chang JH, Tsou MH, Yuen NW, Ng WF, Chan AC, Prat J. Inflammatory pseudotumor-like follicular dendritic cell tumor: a distinctive low-grade malignant intra-abdominal neoplasm with consistent Epstein-Barr virus association. *Am J Surg Pathol* 2001; **25**: 721-731 [PMID: 11395549 DOI: 10.1097/0000478-200106000-00003]
- 4 Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. *Blood* 2016; **127**: 2361-2364 [PMID: 27069255 DOI: 10.1182/blood-2016-03-657379]
- 5 Aparicio Serrano A, Castro Rodríguez J, Gallego Jiménez E, Barrera Baena P. Inflammatory pseudotumor-like follicular dendritic cell sarcoma of the liver. *Rev Esp Enferm Dig* 2021; **113**: 378-379 [PMID: 33371694 DOI: 10.17235/reed.2020.7602/2020]
- 6 Lu SS, Wang Z, Zhao S, Liu WP. [Hepatic inflammatory pseudotumor-like follicular dendritic cell sarcoma with paravertebral metastasis and recurrence: report of a case]. *Zhonghua Bing Li Xue Za Zhi* 2021; **50**: 958-960 [PMID: 34344089 DOI: 10.3760/cma.j.cn112151-20210325-00234]
- 7 Pascariu AD, Neagu AI, Neagu AV, Băjenaru A, Bețianu CI. Hepatic inflammatory pseudotumor-like follicular dendritic cell tumor: a case report. *J Med Case Rep* 2021; **15**: 410 [PMID: 34321082 DOI: 10.1186/s13256-021-02957-5]

- 8 **Jin K**, Li MN, Li S, Li J, Chen N. [Hepatic inflammatory pseudotumor-like follicular dendritic cell sarcoma]. *Zhonghua Gan Zang Bing Za Zhi* 2020; **28**: 172-174 [PMID: 32164072 DOI: 10.3760/cma.j.issn.1007-3418.2020.02.015]
- 9 **Hang JF**, Wang LC, Lai CR. Cytological features of inflammatory pseudotumor-like follicular dendritic cell sarcoma of spleen: A case report. *Diagn Cytopathol* 2017; **45**: 230-234 [PMID: 27775241 DOI: 10.1002/dc.23626]
- 10 **Kwon H**. Inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen. *Turk J Gastroenterol* 2018; **29**: 128-130 [PMID: 29391320 DOI: 10.5152/tjg.2018.17220]
- 11 **Li X**, Shi Z, You R, Li Y, Cao D, Lin R, Huang X. Inflammatory Pseudotumor-Like Follicular Dendritic Cell Sarcoma of the Spleen: Computed Tomography Imaging Characteristics in 5 Patients. *J Comput Assist Tomogr* 2018; **42**: 399-404 [PMID: 29287022 DOI: 10.1097/RCT.0000000000000700]
- 12 **Gong QX**, Fan QH, Zhou ZS, Zhang ZH, Yu MN, Wang Z, Wang C, Zhang WM. [Inflammatory pseudotumor-like follicular dendritic cell tumor of spleen]. *Zhonghua Bing Li Xue Za Zhi* 2008; **37**: 40-44 [PMID: 18509984]
- 13 **Kazemimood R**, Saei Hamedani F, Sharif A, Gaitonde S, Wiley E, Giulianotti PC, Groth JV. A Rare Case of Epstein-Barr Virus Negative Inflammatory Pseudotumor-like Follicular Dendritic Cell Sarcoma Presenting as a Solitary Colonic Mass in a 53-Year-Old Woman; Case Report and Review of Literature. *Appl Immunohistochem Mol Morphol* 2017; **25**: e30-e33 [PMID: 27299190 DOI: 10.1097/PAI.0000000000000405]
- 14 **Pan ST**, Cheng CY, Lee NS, Liang PI, Chuang SS. Follicular Dendritic Cell Sarcoma of the Inflammatory Pseudotumor-like Variant Presenting as a Colonic Polyp. *Korean J Pathol* 2014; **48**: 140-145 [PMID: 24868227 DOI: 10.4132/KoreanJPathol.2014.48.2.140]
- 15 **Shi QY**, Zheng Z, Wu HY, Chen JY, Fan XS. [Colonic inflammatory pseudotumor-like follicular dendritic cell sarcoma: report of a case]. *Zhonghua Bing Li Xue Za Zhi* 2022; **51**: 138-140 [PMID: 35152634 DOI: 10.3760/cma.j.cn112151-20210727-00531]
- 16 **He H**, Xue Q, Tan F, Yang L, Wang X, Gao Y, Mao Y, Mu J, Wang D, Zhao J, Zhao L, Gao S. A rare case of primary pulmonary inflammatory pseudotumor-like follicular dendritic cell sarcoma successfully treated by lobectomy. *Ann Transl Med* 2021; **9**: 77 [PMID: 33553370 DOI: 10.21037/atm-20-4965]
- 17 **Mograbli M**, Stump MS, Luyimbazi DT, Shakhathreh MH, Grider DJ. Pancreatic Inflammatory Pseudotumor-Like Follicular Dendritic Cell Tumor. *Case Rep Pathol* 2019; **2019**: 2648123 [PMID: 31885993 DOI: 10.1155/2019/2648123]
- 18 **Kiryu S**, Takeuchi K, Shibahara J, Uozaki H, Fukayama M, Tanaka H, Maeda E, Akahane M, Ohtomo K. Epstein-Barr virus-positive inflammatory pseudotumour and inflammatory pseudotumour-like follicular dendritic cell tumour. *Br J Radiol* 2009; **82**: e67-e71 [PMID: 19325041 DOI: 10.1259/bjr/66918927]
- 19 **Martins PN**, Reddy S, Martins AB, Facciuto M. Follicular dendritic cell sarcoma of the liver: unusual presentation of a rare tumor and literature review. *Hepatobiliary Pancreat Dis Int* 2011; **10**: 443-445 [PMID: 21813397 DOI: 10.1016/s1499-3872(11)60076-3]
- 20 **Levi Sandri GB**, Colasanti M, Vennarecci G, Ettorre GM. Paraneoplastic arthritis as first symptom of a liver inflammatory pseudotumor-like follicular dendritic cell sarcoma. *Liver Int* 2016; **36**: 1392 [PMID: 27125361 DOI: 10.1111/liv.13148]
- 21 **Xu L**, Ge R, Gao S. Imaging features and radiologic-pathologic correlations of inflammatory pseudotumor-like follicular dendritic cell sarcoma. *BMC Med Imaging* 2021; **21**: 52 [PMID: 33731032 DOI: 10.1186/s12880-021-00584-6]
- 22 **Horiuchi R**, Uchida T, Kojima T, Shikata T. Inflammatory pseudotumor of the liver. Clinicopathologic study and review of the literature. *Cancer* 1990; **65**: 1583-1590 [PMID: 2155699 DOI: 10.1002/1097-0142(19900401)65:7<1583::aid-cnrcr2820650722>3.0.co;2-l]
- 23 **Lizarralde E**, Martínez P, Ibañez T, Gutiérrez A. Primary hepatic lymphoma and primary biliary cirrhosis. *Am J Gastroenterol* 2000; **95**: 562-563 [PMID: 10685781 DOI: 10.1111/j.1572-0241.2000.t01-1-01811.x]
- 24 **Delshad SD**, Ahdoot JJ, Portocarrero DJ. Primary hepatic lymphoma. *Clin Gastroenterol Hepatol* 2010; **8**: e49-e50 [PMID: 19948244 DOI: 10.1016/j.cgh.2009.11.014]
- 25 **Zhang BX**, Chen ZH, Liu Y, Zeng YJ, Li YC. Inflammatory pseudotumor-like follicular dendritic cell sarcoma: A brief report of two cases. *World J Gastrointest Oncol* 2019; **11**: 1231-1239 [PMID: 31908727 DOI: 10.4251/wjgo.v11.i12.1231]
- 26 **Choe JY**, Go H, Jeon YK, Yun JY, Kim YA, Kim HJ, Huh J, Lee H, Shin DH, Kim JE. Inflammatory pseudotumor-like follicular dendritic cell sarcoma of the spleen: a report of six cases with increased IgG4-positive plasma cells. *Pathol Int* 2013; **63**: 245-251 [PMID: 23714251 DOI: 10.1111/pin.12057]
- 27 **Zhao M**, Du X, OuYang B, Li M, Yang H. Inflammatory pseudotumor-like follicular dendritic cell sarcoma mimicking a colonic polyp. *J Gastrointest Surg* 2021; **25**: 2429-2430 [PMID: 33674906 DOI: 10.1007/s11605-021-04961-y]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

